Table 3.
Ongoing and closed phase II trials combining chemotherapy and anti-EGFR.
| Study Name, Trial ID, Country | Method of ctDNA Analysis | Estimated Patients | Setting | Phase | Experimental Arm | Control Arm | Status |
|---|---|---|---|---|---|---|---|
| MoLiMoR, NCT04554836, Germany | OncoBEAM (Sysmex) | 144 | First line | II | FOLFIRI + Cetuximab | FOLFIRI + Bevacizumab | Active, not recruiting |
| CONVERTIX, EudraCT 2017-003242-25, Spain | OncoBEAM (Sysmex) | 40 | Second line | II | FOLFIRI + Panitumumab | NA | Closed |
| CETIDYL, NCT04189055, France |
Idylla (Biocartis) | 72 | ≥Third line | II | Cetuximab +/− Irinotecan | NA | Recruiting |
| KAIROS, EudraCT 2019-001328-36, Italy |
Idylla (Biocartis) | 112 | Second line | II | Cetuximab + Chemo Doublet | NA | Recruiting |
| C-PROWESS, jRCT, s031210565, Japan | OncoBEAM (Sysmex) + Guardant360 (Guardant Health) | 30 | ≥Second line | II | Panitumumab + irinotecan | NA | Recruiting |
NA: not available.